XOMA Royalty Corporation announces cash dividends for Series A and B Preferred Stock, payable July 15, 2025.
Quiver AI Summary
XOMA Royalty Corporation announced that its Board of Directors has approved cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Shareholders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive $0.53906 per share, while holders of the 8.375% Series B Cumulative Perpetual Preferred Stock will receive $0.52344 per depositary share. These dividends will be distributed on or about July 15, 2025, to those on record as of July 3, 2025. XOMA Royalty focuses on acquiring the potential future economic benefits associated with pre-commercial therapeutic candidates and has a growing portfolio of assets linked to various drug products in development.
Potential Positives
- Announcement of cash dividends demonstrates financial strength and commitment to returning value to shareholders.
- Regular dividends indicate positive cash flow and stability in the company's financial operations.
- Authorization of dividends for both Series A and Series B preferred stockholders supports the company's credibility and trust with investors.
Potential Negatives
- The announcement of cash dividends may indicate that the company is managing cash flow carefully, potentially raising concerns about its overall financial health and ability to invest in growth initiatives.
- The reliance on preferred stock dividends could suggest that the company might not be generating sufficient income from its operational activities, leading to increased scrutiny from investors.
- Investors may be wary regarding the company's portfolio largely consisting of investigational compounds, as the press release emphasizes that efficacy and safety have not been established, posing a risk to future revenue.
FAQ
What cash dividends were declared by XOMA Royalty Corporation?
XOMA Royalty Corporation declared cash dividends for Series A and Series B Cumulative Preferred Stock, with amounts of $0.53906 and $0.52344 respectively.
When will the preferred dividends be paid?
The preferred dividends will be paid on or about July 15, 2025, to holders of record as of July 3, 2025.
What is XOMA Royalty Corporation's business focus?
XOMA Royalty Corporation focuses on acquiring future economics from pre-commercial therapeutic candidates, supporting biotech companies in drug development.
What are the commercial assets in XOMA's portfolio?
Commercial assets include VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA® among others.
How can I find more information about XOMA Royalty Corporation?
For more information about XOMA Royalty Corporation and its portfolio, you can visit their website at www.xoma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XOMA Insider Trading Activity
$XOMA insiders have traded $XOMA stock on the open market 20 times in the past 6 months. Of those trades, 12 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $XOMA stock by insiders over the last 6 months:
- PARTNERS L P/IL BVF has made 0 purchases and 6 sales selling 1,043,440 shares for an estimated $27,626,507.
- JOSEPH M LIMBER has made 5 purchases buying 30,000 shares for an estimated $760,144 and 0 sales.
- OWEN HUGHES (Chief Executive Officer) sold 25,637 shares for an estimated $650,667
- THOMAS M. BURNS (SVP, Finance & CFO) sold 10,482 shares for an estimated $266,033
- BRADLEY SITKO (Chief Investment Officer) has made 7 purchases buying 6,679 shares for an estimated $162,125 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XOMA Hedge Fund Activity
We have seen 27 institutional investors add shares of $XOMA stock to their portfolio, and 34 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 804,970 shares (+253.7%) to their portfolio in Q1 2025, for an estimated $16,043,052
- BVF INC/IL removed 650,717 shares (-17.9%) from their portfolio in Q1 2025, for an estimated $12,968,789
- ACUITAS INVESTMENTS, LLC removed 55,030 shares (-90.7%) from their portfolio in Q1 2025, for an estimated $1,096,747
- EVERSEPT PARTNERS, LP removed 50,400 shares (-52.8%) from their portfolio in Q1 2025, for an estimated $1,004,472
- OCCUDO QUANTITATIVE STRATEGIES LP removed 20,925 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $417,035
- ELLSWORTH ADVISORS, LLC removed 19,475 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $511,803
- MARSHALL WACE, LLP added 14,533 shares (+inf%) to their portfolio in Q1 2025, for an estimated $289,642
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XOMA Analyst Ratings
Wall Street analysts have issued reports on $XOMA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 01/08/2025
To track analyst ratings and price targets for $XOMA, check out Quiver Quantitative's $XOMA forecast page.
Full Release
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.
The preferred dividends will be paid on or about July 15, 2025, to respective holders of record at the close of business on July 3, 2025.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO ® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY ® [coagulation factor IX (recombinant)], and DSUVIA ® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
| Investor contact: | Media contact: |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty Corporation | KV Consulting & Management |
| +1-646-438-9754 | +1-310-403-8951 |
| [email protected] | [email protected] |
